Cyclohexanecarboxylic Acids

Publication Title: 
American Family Physician

The results of large clinical trials have led physicians and patients to question the safety of hormone therapy for menopause. In the past, physicians prescribed hormone therapy to improve overall health and prevent cardiac disease, as well as for symptoms of menopause. Combined estrogen/progestogen therapy, but not estrogen alone, increases the risk of breast cancer when used for more than three to five years.

Author(s): 
Hill, D. Ashley
Crider, Mark
Hill, Susan R.
Publication Title: 
American Family Physician

The results of large clinical trials have led physicians and patients to question the safety of hormone therapy for menopause. In the past, physicians prescribed hormone therapy to improve overall health and prevent cardiac disease, as well as for symptoms of menopause. Combined estrogen/progestogen therapy, but not estrogen alone, increases the risk of breast cancer when used for more than three to five years.

Author(s): 
Hill, D. Ashley
Crider, Mark
Hill, Susan R.
Publication Title: 
The Annals of Pharmacotherapy

OBJECTIVE: To evaluate the efficacy of gabapentin for the treatment of uremic pruritus (UP). DATA SOURCES: Literature retrieval was accessed through MEDLINE (1950-March week 3, 2008; In-Process & Other Non-Indexed Citations, April 1, 2008) and International Pharmaceutical Abstracts (1970-March 2008) using the terms gabapentin, pruritus, itch, urem$ (truncated), dialysis, and kidney disease. The Google Scholar search engine was used to identify articles that MEDLINE did not capture with the described search terms.

Author(s): 
Vila, Tania
Gommer, Jennifer
Scates, Ann C.
Publication Title: 
The Cochrane Database of Systematic Reviews

BACKGROUND: Hot flushes are common in women with a history of breast cancer. Hormonal therapies are known to reduce these symptoms but are not recommended in women with a history of breast cancer due to their potential adverse effects. The efficacy of non-hormonal therapies is still uncertain. OBJECTIVES: To assess the efficacy of non-hormonal therapies in reducing hot flushes in women with a history of breast cancer.

Author(s): 
Rada, Gabriel
Capurro, Daniel
Pantoja, Tomas
Corbalán, Javiera
Moreno, Gladys
Letelier, Luz M.
Vera, Claudio
Publication Title: 
The Cochrane Database of Systematic Reviews

BACKGROUND: Hot flushes are common in women with a history of breast cancer. Hormonal therapies are known to reduce these symptoms but are not recommended in women with a history of breast cancer due to their potential adverse effects. The efficacy of non-hormonal therapies is still uncertain. OBJECTIVES: To assess the efficacy of non-hormonal therapies in reducing hot flushes in women with a history of breast cancer.

Author(s): 
Rada, Gabriel
Capurro, Daniel
Pantoja, Tomas
Corbalán, Javiera
Moreno, Gladys
Letelier, Luz M.
Vera, Claudio
Publication Title: 
American Family Physician

The results of large clinical trials have led physicians and patients to question the safety of hormone therapy for menopause. In the past, physicians prescribed hormone therapy to improve overall health and prevent cardiac disease, as well as for symptoms of menopause. Combined estrogen/progestogen therapy, but not estrogen alone, increases the risk of breast cancer when used for more than three to five years.

Author(s): 
Hill, D. Ashley
Crider, Mark
Hill, Susan R.
Publication Title: 
Obstetrics and Gynecology Clinics of North America

This article focuses on the cause, pathophysiology, differential diagnosis of, and treatment options for vasomotor symptoms. In addition, it summarizes important points for health care providers caring for perimenopausal and postmenopausal women with regard to health maintenance, osteoporosis, cardiovascular disease, and vaginal atrophy.

Author(s): 
Krause, Miriam S.
Nakajima, Steven T.
Publication Title: 
The Journal of Biological Chemistry
Author(s): 
Davidson, B. E.
Blackburn, E. H.
Dopheide, T. A.
Publication Title: 
Menopause (New York, N.Y.)

OBJECTIVE: Based on a common mechanism of action with gabapentin, we investigated the effects of L-methionine on hot flashes in postmenopausal women. METHODS: After a 1-week baseline period, 51 postmenopausal women experiencing at least five moderate-severe hot flashes per day were randomized to one of three groups in a 13:13:25 ratio: placebo/placebo, placebo/L-methionine, or L-methionine/L-methionine, respectively (phase 1/phase 2). Phase 1 was 12 weeks long, and phase 2 was 8 weeks long. Participants took 1 g PO BID in phase 1 and 2 g PO BID in phase 2 of either L-methionine or placebo.

Author(s): 
Guttuso, Thomas
McDermott, Michael P.
Ng, Phillip
Kieburtz, Karl
Publication Title: 
The Cochrane Database of Systematic Reviews

BACKGROUND: Hot flushes are common in women with a history of breast cancer. Hormonal therapies are known to reduce these symptoms but are not recommended in women with a history of breast cancer due to their potential adverse effects. The efficacy of non-hormonal therapies is still uncertain. OBJECTIVES: To assess the efficacy of non-hormonal therapies in reducing hot flushes in women with a history of breast cancer.

Author(s): 
Rada, Gabriel
Capurro, Daniel
Pantoja, Tomas
Corbalán, Javiera
Moreno, Gladys
Letelier, Luz M.
Vera, Claudio

Pages

Subscribe to RSS - Cyclohexanecarboxylic Acids